Clinuvel Pharmaceuticals

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Fibonacci Extensions

Score

0.5

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 7 61.6 0.86% 6.00% 24.2% -23.9% 121.5%
SHORT 8 40.8 0.25% 0.33% 12.3% -7.9% -23.0%

Summary

Technical Analysis

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

FIBONACCI EXTENSION


Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.


Clinuvel Pharmaceuticals (ASX:CUV) : The current Fibonacci Extension levels are:
(23.61%) $29.73
(38.2%) $30.36
(50%) $30.88
(61.8%) $31.39

The current support levels are:
(78.6%) $32.12
(100%) $33.05
(138.2%) $34.71
(161.8%) $35.74
(261.8%) $40.09
(423.61%) $47.13



Fibonacci extensions are used in Fibonacci retracement to predict spaces of resistance and support in the market. These extensions involve all levels drawn past the basic 100% level they are frequently used by traders to determine areas that will bring in profits.

Calculation: Fibonacci Extensions:
1) Uptrend: D = B — (A — B) x N%;
2) Downtrend: D = B + (B — A) x N %;
3) Fibonacci Levels:
61.8%
100%
138.2%
161.8%
261.8%
423.6%;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Fibonacci Extensions

Download
Company Close Change(%) Volume Value Signal
TZN Terramin Australia 0.04 8.1 171,000 -0.02 BEARISH
MNS Milnes Holdings 0.11 4.8 156,309 -0.08 BEARISH
ADA Adacel Technologies 0.48 4.4 50,299 -0.06 BEARISH
CEN Central Australian Phosphate 6.46 2.9 92,401 -1.66 BEARISH
CVC CVC 2.18 2.8 35,000 -0.16 BEARISH
SXL Southern Cross Media 0.92 2.8 1,376,211 -0.12 BEARISH
LNG Liquefied Natural Gas 0.21 2.5 1,377,062 -0.08 BEARISH
MTO Moto Goldmines 2.11 2.4 12,484 -0.62 BEARISH
ALK Alkane Exploration 0.63 2.4 458,752 -0.23 BEARISH
CIA Champion Iron 2 2.3 559,046 -0.5 BEARISH